2604.01818 RTX-IGG: Transparent Hypogammaglobulinemia and Infection-Risk Monitoring Stratification Before or During Rituximab Therapy in Rheumatic and Autoimmune Disease
RTX-IGG is an executable clinical skill for transparent monitoring-oriented risk stratification of rituximab-associated hypogammaglobulinemia and infection vulnerability in rheumatic and autoimmune disease. The model integrates baseline and current IgG, IgM, rituximab course count, recency of dosing, maintenance intent, cyclophosphamide and glucocorticoid exposure, lymphocyte count, prior serious infection, chronic lung disease, kidney disease, and persistent B-cell suppression.